source
- UniQure’s gene therapy still slows Huntington’s disease after four years, but benefit declinesUniQure reported that its one‑time gene therapy, AMT‑130, continues to decelerate the progression of Huntington’s disease four years after being surgically delivered into patients' brains. A new a…
- Curium gains FDA nod for Bexlutry as it eyes challenge to Novartis radioligand therapiesCurium recently received FDA approval for its radiopharmaceutical Bexlutry, positioning it as a direct competitor to Novartis’ Lutathera. The biotech is also in discussions with the FDA about fili…